biostudies-literatureManyazewal TFIC NIH HHSNIAID NIH HHSMedical Research Council101820https://www.ebi.ac.uk/biostudies/studies/S-EPMC9853306biostudies-literatureUnknown56<h4>Background</h4>The success of a tuberculosis digital adherence technology relies on patients' satisfaction with and the usability of the technology. This study aimed to evaluate treatment satisfaction and usability of a digital medication event reminder and monitor (MERM) device for patients with tuberculosis to address the prespecified secondary endpoint of the SELFTB trial.<h4>Methods</h4>In this multicenter, randomised controlled trial, adults (≥18 years) with new or previously treated, bacteriologically-confirmed, drug-sensitive pulmonary tuberculosis who were eligible to start anti-tuberculosis therapy were recruited from 10 healthcare facilities in Ethiopia. With a computer-generated random number sequence, participants were randomly assigned 1:1 to receive a 15-day tuberculosis EClinicalMedicinePatient-reported usability and satisfaction with electronic medication event reminder and monitor device for tuberculosis: a multicentre, randomised controlled trial.PMC9853306D43 TW009127P30 AI168386MR/M025470/1P30 AI050409Getinet TFuad OManyazewal TGetahun BFekadu AMarconi VCBobosha KWoldeamanuel YHolland DPHoover AfalsePatient-reported usability and satisfaction with electronic medication event reminder and monitor device for tuberculosis: a multicentre, randomised controlled trial.<h4>Background</h4>The success of a tuberculosis digital adherence technology relies on patients' satisfaction with and the usability of the technology. This study aimed to evaluate treatment satisfaction and usability of a digital medication event reminder and monitor (MERM) device for patients with tuberculosis to address the prespecified secondary endpoint of the SELFTB trial.<h4>Methods</h4>In this multicenter, randomised controlled trial, adults (≥18 years) with new or previously treated, bacteriologically-confirmed, drug-sensitive pulmonary tuberculosis who were eligible to start anti-tuberculosis therapy were recruited from 10 healthcare facilities in Ethiopia. With a computer-generated random number sequence, participants were randomly assigned 1:1 to receive a 15-day tuberculosis 2023-01-01T00:00:00Z2023 Feb2026-05-28T20:08:58.541Z2025-02-19T04:45:43.212ZS-EPMC98533063668439510.1016/j.eclinm.2022.101820